Weird Resveratrol Results from Human Trial

Resveratrol has long been in the debate spotlight for its anti-aging and health benefits. It seemed to storm onto the scene in the mid 2000’s. 

The problem has always been (or at least believed to be) it’s poor bioavailability. As a result you can find a variety of highly bioavailable options in your supplement aisle. 

Still no one is sure if they do much of anything. This latest study only seems to further confirm the belief.  

 Their subjects were healthy men, which is a nice start to any study. After 28 days of supplementing and pre and post cognitive tests they found that Resveratrol provided no cognitive benefit. It appears in this case resveratrol won’t make you smarter. 

An interesting and bad finding was that it also increased diastolic blood pressure. Something all anabolic users should be wanting to decrease


The effects of chronic trans-resveratrol supplementation on aspects of cognitive function, mood, sleep, health and cerebral blood flow in healthy, young humans.
Br J Nutr. 2015 Sep 7;:1-11
Authors: Wightman EL, Haskell-Ramsay CF, Reay JL, Williamson G, Dew T, Zhang W, Kennedy DO

Single doses of resveratrol have previously been shown to increase cerebral blood flow (CBF) with no clear effect on cognitive function or mood in healthy adults. Chronic resveratrol consumption may increase the poor bioavailability of resveratrol or otherwise potentiate its psychological effects.

In this randomised, double-blind, placebo-controlled, parallel-groups study, a total of sixty adults aged between 18 and 30 years received either placebo or resveratrol for 28 d. On the 1st and 28th day of treatment, the performance of cognitively demanding tasks (serial subtractions, rapid visual information processing and 3-Back) (n 41 complete data sets) was assessed, alongside blood pressure (n 26) and acute (near-IR spectroscopy (NIRS)) and chronic (transcranial Doppler) measures of CBF (n 46).

Subjective mood, sleep quality and health questionnaires were completed at weekly intervals (n 53/54). The results showed that the cognitive effects of resveratrol on day 1 were restricted to more accurate but slower serial subtraction task performance. The only cognitive finding on day 28 was a beneficial effect of resveratrol on the accuracy of the 3-Back task before treatment consumption.

Subjective ratings of ‘fatigue’ were significantly lower across the entire 28 d in the resveratrol condition. Resveratrol also resulted in modulation of CBF parameters on day 1, as assessed by NIRS, and significantly increased diastolic blood pressure on day 28. Levels of resveratrol metabolites were significantly higher both before and after the day’s treatment on day 28, in comparison with day 1.

These results confirm the acute CBF effects of resveratrol and the lack of interpretable cognitive effects.